Patient-Driven Drug Development Requires New Transparency Policies

If advocacy groups are going to play a greater role in drug development, they need more access to sponsors' data and interactions with the US FDA, and more information about how the agency uses patient preference data, Parent Project Muscular Dystrophy rep says.